JP6811241B2 - ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト - Google Patents
ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト Download PDFInfo
- Publication number
- JP6811241B2 JP6811241B2 JP2018530001A JP2018530001A JP6811241B2 JP 6811241 B2 JP6811241 B2 JP 6811241B2 JP 2018530001 A JP2018530001 A JP 2018530001A JP 2018530001 A JP2018530001 A JP 2018530001A JP 6811241 B2 JP6811241 B2 JP 6811241B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- urea
- alkoxy
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265885P | 2015-12-10 | 2015-12-10 | |
| US62/265,885 | 2015-12-10 | ||
| PCT/US2016/065504 WO2017100390A1 (en) | 2015-12-10 | 2016-12-08 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536687A JP2018536687A (ja) | 2018-12-13 |
| JP2018536687A5 JP2018536687A5 (enExample) | 2020-01-23 |
| JP6811241B2 true JP6811241B2 (ja) | 2021-01-13 |
Family
ID=57590898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530001A Active JP6811241B2 (ja) | 2015-12-10 | 2016-12-08 | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10717708B2 (enExample) |
| EP (1) | EP3414227B1 (enExample) |
| JP (1) | JP6811241B2 (enExample) |
| KR (1) | KR102772801B1 (enExample) |
| CN (1) | CN108368046B (enExample) |
| AU (1) | AU2016366211B2 (enExample) |
| BR (1) | BR112018011046A2 (enExample) |
| CA (1) | CA3007972A1 (enExample) |
| EA (1) | EA034227B1 (enExample) |
| ES (1) | ES2901471T3 (enExample) |
| IL (1) | IL259791B (enExample) |
| MX (1) | MX386387B (enExample) |
| SG (1) | SG11201804589TA (enExample) |
| WO (1) | WO2017100390A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020523327A (ja) * | 2017-06-09 | 2020-08-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018010155A8 (pt) * | 2015-11-24 | 2019-02-26 | Bristol Myers Squibb Co | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca |
| US10717708B2 (en) | 2015-12-10 | 2020-07-21 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| ES2869129T3 (es) * | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Agonistas de piperidinona del receptor 2 de péptidos formilados |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CN110997653B (zh) * | 2017-06-09 | 2023-06-06 | 百时美施贵宝公司 | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 |
| KR102803660B1 (ko) | 2018-03-05 | 2025-05-02 | 브리스톨-마이어스 스큅 컴퍼니 | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 |
| AR114383A1 (es) * | 2018-03-09 | 2020-08-26 | Gruenenthal Gmbh | Piperidinas o piperidonas sustituidas con urea y fenilo |
| US12281108B2 (en) | 2018-11-26 | 2025-04-22 | Bristol-Myers Squibb Company | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists |
| KR20220024551A (ko) * | 2019-06-18 | 2022-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | 비아릴 디알킬 포스핀 옥시드 fpr2 효능제 |
| EP3789378A1 (en) * | 2019-09-06 | 2021-03-10 | Grünenthal GmbH | Piperidines or piperidones substituted with urea and heteroaryl |
| EP4196471A1 (en) * | 2020-08-12 | 2023-06-21 | Bristol-Myers Squibb Company | Oxopyrrolidine urea fpr2 agonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060859A2 (en) | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| WO2006063113A2 (en) * | 2004-12-07 | 2006-06-15 | Portola Pharmaceuticals, Inc. | Ureas as factor xa inhibitors |
| BR112015021392B1 (pt) * | 2013-03-06 | 2021-11-16 | Allergan, Inc | Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas |
| BR112016011755B1 (pt) | 2013-11-28 | 2023-05-02 | Kyorin Pharmaceutical Co., Ltd | Derivado de ureia ou sal farmacologicamente aceitável do mesmo, seu uso e composição farmacêutica que os compreende |
| WO2016189877A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| BR112017024966A2 (pt) * | 2015-05-27 | 2018-08-07 | Kyorin Seiyaku Kk | derivado de ureia ou sal farmacologicamente aceitável do mesmo |
| BR112018010155A8 (pt) | 2015-11-24 | 2019-02-26 | Bristol Myers Squibb Co | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca |
| US10717708B2 (en) * | 2015-12-10 | 2020-07-21 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| WO2018227065A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| ES2869129T3 (es) | 2017-06-09 | 2021-10-25 | Bristol Myers Squibb Co | Agonistas de piperidinona del receptor 2 de péptidos formilados |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CN110997653B (zh) | 2017-06-09 | 2023-06-06 | 百时美施贵宝公司 | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 |
-
2016
- 2016-12-08 US US15/776,933 patent/US10717708B2/en active Active
- 2016-12-08 ES ES16816564T patent/ES2901471T3/es active Active
- 2016-12-08 CN CN201680072467.4A patent/CN108368046B/zh active Active
- 2016-12-08 EP EP16816564.5A patent/EP3414227B1/en active Active
- 2016-12-08 BR BR112018011046A patent/BR112018011046A2/pt active Search and Examination
- 2016-12-08 KR KR1020187019246A patent/KR102772801B1/ko active Active
- 2016-12-08 JP JP2018530001A patent/JP6811241B2/ja active Active
- 2016-12-08 SG SG11201804589TA patent/SG11201804589TA/en unknown
- 2016-12-08 EA EA201891143A patent/EA034227B1/ru not_active IP Right Cessation
- 2016-12-08 WO PCT/US2016/065504 patent/WO2017100390A1/en not_active Ceased
- 2016-12-08 AU AU2016366211A patent/AU2016366211B2/en not_active Ceased
- 2016-12-08 MX MX2018006635A patent/MX386387B/es unknown
- 2016-12-08 CA CA3007972A patent/CA3007972A1/en not_active Abandoned
-
2018
- 2018-06-04 IL IL259791A patent/IL259791B/en unknown
-
2020
- 2020-06-11 US US16/898,889 patent/US11530183B2/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020523327A (ja) * | 2017-06-09 | 2020-08-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
| JP7183193B2 (ja) | 2017-06-09 | 2022-12-05 | ブリストル－マイヤーズ スクイブ カンパニー | ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
Also Published As
| Publication number | Publication date |
|---|---|
| MX386387B (es) | 2025-03-18 |
| SG11201804589TA (en) | 2018-06-28 |
| EA034227B1 (ru) | 2020-01-20 |
| CN108368046A (zh) | 2018-08-03 |
| ES2901471T3 (es) | 2022-03-22 |
| KR20180091876A (ko) | 2018-08-16 |
| US20180327358A1 (en) | 2018-11-15 |
| US20200299237A1 (en) | 2020-09-24 |
| IL259791A (en) | 2018-07-31 |
| JP2018536687A (ja) | 2018-12-13 |
| KR102772801B1 (ko) | 2025-02-24 |
| AU2016366211A1 (en) | 2018-07-26 |
| MX2018006635A (es) | 2018-08-01 |
| CN108368046B (zh) | 2022-01-14 |
| US10717708B2 (en) | 2020-07-21 |
| BR112018011046A2 (pt) | 2018-11-21 |
| EP3414227A1 (en) | 2018-12-19 |
| AU2016366211B2 (en) | 2021-06-17 |
| CA3007972A1 (en) | 2017-06-15 |
| WO2017100390A1 (en) | 2017-06-15 |
| US11530183B2 (en) | 2022-12-20 |
| IL259791B (en) | 2021-08-31 |
| EA201891143A1 (ru) | 2018-11-30 |
| EP3414227B1 (en) | 2021-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6811241B2 (ja) | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト | |
| KR102803660B1 (ko) | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 | |
| JP6817305B2 (ja) | アペリン受容体アゴニストおよびその使用方法 | |
| KR102623473B1 (ko) | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 | |
| CN106061968B (zh) | 四唑酮-取代的二氢吡啶酮mgat2抑制剂 | |
| AU2014274354A1 (en) | Dihydropyridinone MGAT2 inhibitors | |
| JP7494224B2 (ja) | ビアリールジアルキルホスフィンオキシドｆｐｒ２アゴニスト | |
| CN116057055A (zh) | 氧代吡咯烷脲类fpr2激动剂 | |
| JP7771157B2 (ja) | オキソピロリジン ｆｐｒ２アゴニスト | |
| JP2023546371A (ja) | アミノイミダゾールｆｐｒ２アゴニスト |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191206 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201112 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201208 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201214 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6811241 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |